1. Home
  2. INTC vs GILD Comparison

INTC vs GILD Comparison

Compare INTC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intel Corporation

INTC

Intel Corporation

HOLD

Current Price

$45.13

Market Cap

259.1B

Sector

Technology

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$135.44

Market Cap

154.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTC
GILD
Founded
1968
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.1B
154.7B
IPO Year
N/A
1992

Fundamental Metrics

Financial Performance
Metric
INTC
GILD
Price
$45.13
$135.44
Analyst Decision
Hold
Buy
Analyst Count
34
21
Target Price
$41.63
$128.62
AVG Volume (30 Days)
122.5M
6.2M
Earning Date
01-22-2026
02-10-2026
Dividend Yield
N/A
2.32%
EPS Growth
N/A
6514.05
EPS
N/A
6.42
Revenue
$52,853,000,000.00
$29,087,000,000.00
Revenue This Year
$3.47
$3.67
Revenue Next Year
$5.24
$3.43
P/E Ratio
N/A
$21.16
Revenue Growth
N/A
2.79
52 Week Low
$17.67
$92.21
52 Week High
$54.60
$136.30

Technical Indicators

Market Signals
Indicator
INTC
GILD
Relative Strength Index (RSI) 52.48 69.77
Support Level $46.71 $120.95
Resistance Level $54.60 $124.48
Average True Range (ATR) 2.85 4.07
MACD 0.61 1.30
Stochastic Oscillator 39.33 95.52

Price Performance

Historical Comparison
INTC
GILD

About INTC Intel Corporation

Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and led the semiconductor industry down the path of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel is seeking to reinvigorate its chip manufacturing business, Intel Foundry, while developing leading-edge products within its Intel Products business segment.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: